SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical
stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases,
today announced its participation in the following upcoming investor conferences:
- Wells Fargo Securities 2017 Healthcare Conference in Boston, MA on Wednesday, September 6, 2017 at 10:15
a.m. ET
- 2017 Cantor Fitzgerald Global Healthcare Conference in New York, NY on Wednesday, September 27, 2017 at 8:00
a.m. ET
A live webcast of each presentation will be available by visiting the Investors section of MyoKardia’s
website at http://investors.myokardia.com. A replay of both webcasts will be available on
the MyoKardia website for 90 days following each conference.
About MyoKardia
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and
commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the
treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical
defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of
therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic
cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly
MYK-461). Mavacamten is a novel, oral, allosteric modulator of cardiac myosin that reduced hypercontractility in Phase 1 clinical
studies of HCM patients. In April 2016, the U.S. Food and Drug Administration granted Orphan Drug Designation for
mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, a subset of HCM. MyoKardia is
currently studying mavacamten in PIONEER-HCM. MYK-491, MyoKardia’s second product candidate, is designed to increase the overall
extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating
MYK-491 in a Phase 1 study in healthy volunteers. A cornerstone of the MyoKardia platform is the Sarcomeric Human
Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and
families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for
patients with serious cardiovascular disease through bold and innovative science.
Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200 beth@sternir.com Media Contact: Steven Cooper Edelman 415-486-3264 steven.cooper@edelman.com
